What was studied?
Seventy-one patients with heart failure and reduced ejection fraction were randomized in a double-blind comparison of elamipretide and placebo. Cardiac magnetic resonance imaging assessed left-ventricular end-systolic volume after four weeks.
What did the researchers report?
Changes in the primary ventricular-volume measurement did not differ significantly between either active group and placebo. Ejection-fraction changes also did not show a significant group difference in the reported analysis.
What are the limits?
A plausible mitochondrial mechanism does not guarantee a measurable clinical response. The brief exposure period and specific heart-failure population limit what this neutral trial can exclude, but the result should not be rewritten as proof of benefit or transferred to other formulations.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.